SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative ...
Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results